Steve Parsons: We’ll talk about the number of targeted heart failure hospitals and clinics that have activated with at least a couple of patients on therapy. We’ll talk about the number of unique patients that have been treated. So you can see the breadth of that. We’ll talk a little bit more about Medicare Part D, payer formulary wins and placement status as that arises as we have more information. And of course, .
John Tucker: Yes. So I think those are the things, Nik, and I. — and I’m going to quote that’s what we’re anticipating. We’re three weeks in data. I think we want to understand what’s the most beneficial things to communicate to the Street. And those are the things I think you’ll learn. Those are the things we’re planning on now. I think they could change in two months, but we just want to make sure we’re communicating what we think are the most telling things and the progress of the launch.
Nik Gasic: That’s very helpful. Also a quick follow-up as well. I was wondering if you could give us a sense of some of the commercial strategies you’ve been implementing to drive awareness among patients, subscribers, et cetera. Maybe which ones you’ve had the most success with so far?
John Tucker: Steve?
Steve Parsons: Yes. So we’re doing the traditional things, digital advertisements in the key targeted journals, journals associated with Heart Failure Society of America, heart failure nurses. Had launched the American College of Cardiology, sent out an e-mail blast announcing FUROSCIX availability to about 15,000 members that are dealing with heart failure. The Heart Failure Society of America did the same thing on our behalf. We’re continuing to do digital ads, banner ads announcing our campaign, announcing the availability of FUROSCIX. So it’s what big pharma does. It’s omnichannel marketing, like others do, just very, very targeted towards the folks that we are going after in the early launch period.
John Tucker: And if we were — as you know, we’re in a prelaunch brand awareness campaign. And actually, we’re able to measure that prior to launch, and we’re really impressed with what we saw with aided awareness on the brand name, and then unaided awareness as well. So it’s a good baseline. We’ve been very happy with the interest we’ve seen in the field. We’ve had phone calls into various people in the office asking if they could talk to a rep. We’ve had a number of inquiries on the website. We’ve had reps in the field that walked in and doctor will be — doctor’s office will tell them that they’re booked. And then we talked a little bit about what we’re doing and the nurse comes back. And says, we’re scheduling a lunch we have for tomorrow, will you come in and do an in-service.
These in-services are really key to us. We really think it’s just critical that these offices and clinics know exactly who to use FUROSCIX on and how to use it. So we’re teaching the doctor, teaching the staff on how FUROSCIX works, how to use it and as importantly, how to show patients. Now we want offices interacting with those patients and training them, but we’re also supporting the patients with instructions for use, with videos online, videos that they can access as well as calls from the specialty pharmacy based on — with any questions they have. So these in services have been great. The interest, the doctors are pulling in their entire staff. Sometimes we’re doing two or three sets of in services in an office that can last one to two hours at some of the biggest hospitals from Duke to State Western.
Northwestern, Emory, WashU, I mean just exactly where we want to be. So we’re really enthused with the awareness of the product when we launched and the enthusiasm to talk to us when we’re out there.
Nik Gasic: Very helpful. Thanks for all update. I’ll hop back in the queue.
